THE GLOBAL COVID-19 VACCINE MARKET SIZE IS VALUED AT USD 35 BILLION AND IS EXPECTED TO REACH USD 42 BILLION BY 2022, REPRESENTING A GROWTH OF 6%

COVID-19 Vaccine Market Size, Share, Trends Analysis Report by Technology (Vector-based, Nucleic acid-based, Protein-based, and Whole Virus); and Geography (APAC, North America, Europe, Latin America, and Middle East & Africa); Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022–2024

GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

207 Pages

61 Tables

76 Charts

5 Regions

20 Countries

27 Companies

2 Market Segment

GLOBAL COVID-19 VACCINE MARKET REPORT SCOPE

Report Attribute Details
MARKET SIZE (2021) USD 35 BILLION
Base Year 2021
Forecast Year 2022-2024
Market Segments Technology (Vector-based, Nucleic acid-based, Protein-based, and Whole Virus)
Geographic Analysis North America, Europe, APAC, Latin America, and Middle East & Africa
Countries Covered US, Canada, UK, Germany, France, Spain, Russia, Italy, China, India, Japan, South Korea, Australia, Brazil, Mexico, South Africa, Saudi Arabia, Turkey, Egypt, and UAE

COVID-19 VACCINE PIPELINE INSIGHTS

The global COVID-19 vaccine market size will be valued at USD 35 billion in 2021 and is expected to reach USD 42 billion by 2022, growing 6% during 2021-2022. Constant focus by government agencies and several vaccine manufacturers to prevent human and economic losses due to the COVID-19 virus across the world is expected to boost the market's growth. With several vendors implementing new strategies, including combining the phase 1 & 2 clinical trial stages and faster regulatory approvals from health agencies, the availability of vaccine doses across the globe is likely to grow during the forecast period.

In response to the COVID-19 pandemic, there is a rapid expansion of novel COVID-19 vaccines in the pipeline. The role of public-private partnerships is further accelerating the vaccine development process. Increased vaccine development efforts across the world have helped generate a broad pipeline of vaccines and novel delivery mechanisms to achieve global immunization in the expected time. Hence, high investments in COVID-19 vaccine development programs worldwide increased manufacturing capacities, and the establishment of new PPPs driving R&D activities are likely to boost the global COVID-19 vaccine market.

J&J’s non-replicating viral vector vaccine has successfully entered its third phase. Novavax’s Nanoparticle COVID vaccine has demonstrated strong efficacy in the Phase 3 UK trial. Sensing the urgency to curb the COVID-pandemic, several manufacturers have entered into the third phase of the vaccine's clinical trials. Johnson & Johnson (J&J), Novavax, and CanSino Biologics have reported promising results during the third phase. J&J is likely to end the practice of two-dose as the company is about to roll out its easier-to-use, single-dose COVID-19 vaccine.

SNIPPETS

  • In APAC, China, India, Japan, South Korea, and Australia are expected to be key major revenue contributors to the coronavirus vaccine market because of the high demand for immunization.
  • APAC is expected to account for the highest revenue share in the global COVID-19 vaccine market because of high-populated countries such as India and China.
  • The UK is likely to constitute 14% of the Europe market because of the high prevalence of the COVID-19 virus.
  • North America, especially the US, is likely to emerge as one of the largest markets as the region is reeling under the coronavirus's onslaught.

GLOBAL COVID-19 VACCINE MARKET SEGMENTATION

This research report includes a detailed segmentation by

  • Technology
  • Geography

INSIGHTS BY TECHNOLOGY  

Protein-based vaccines constitute the highest COVID-19 vaccine market share as they contain the purified pieces of pathogen rather than the whole pathogen to trigger the immune response. In the absence of any significant adverse effect on the human body, these vaccines are likely to observe substantial growth during the forecast period. Novavax, Chinese Academy of Sciences, and GSK/Sanofi are the major manufacturers that have approved protein-based vaccines for emergence use authorization. Protein-based vaccines can be used in patients with compromised immune responses.

Viral-vector-based vaccines account for the second-largest market share. The availability of well-established vaccine manufacturing infrastructure, which can help developing an effective vaccine in a short period, is a significant factor contributing to the growth of viral-based vaccines. Other major factors influencing the growth are high suitability for compromised immune systems patients and a relatively simple manufacturing process. However, a high adverse effect on humans is likely to decrease market growth. Sinovac, Sinopharm, CNBG, Bharat Biotech, Valneva, and Medicago are the major viral-based vaccine manufacturers.

INSIGHTS BY GEOGRAPHY

The outbreak of the COVID-19 pandemic was witnessed across the globe. Countries such as the UK, the US, Italy, Spain, India, China were the most affected; however, Middle East and African countries observed a low to moderate occurrence rate. The APAC market dominated the global COVID-19 vaccine market with over 58% share, followed by Europe with 15% and North America with 12%. The Middle East and Africa, and Latin America accounted for 10 % and 6%, respectively. Since the outbreak of the disease in 2019, which eventually was declared a pandemic by the WHO in March 2020, the spread has been thick and fast, swaying country after country and region after region. Most developed regions such as North America and Europe suffered high mortality. While the APAC region witnessed an unprecedented surge in the spread of the infection, the death rate was comparatively low. Several western countries observed a second wave of COVID-19 infection in mid-2020, causing further loss of lives, thereby driving vaccine manufacturers to speed up their efforts. Over 250 vaccine developers across the globe are working on several platforms to produce an effective vaccine. However, most COVID-19 vaccine-related R&D activities are focused on North America, with 46% developers of the confirmed active vaccine candidates compared with 18% in China, 18% in Asia (excluding China) and Australia, and 18% in Europe. Over 50% of vaccines made up to the clinical trial phase are in the North America, Europe, and APAC regions.

INSIGHTS BY VENDORS

AstraZeneca, GlaxoSmithKline, Moderna, Gamaleya, Bharat Biotech, and Pfizer are the major manufacturers of COVID-19 vaccines. Biotechnology and pharmaceutical industries are intensely competitive and are characterized by rapid and significant technological progress in vaccine development. Multiple products have been approved by the USFDA, EU, and other regulatory bodies for emergency use authorization (EUA) worldwide. Many products are manufactured using the latest vaccine platforms in the market.

The global COVID-19 vaccine market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:

By Technology

  • Vector-based
  • Nucleic acid-based
  • Protein-based
  • Whole Virus

By Geography

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • Russia
  • APAC
    • China
    • Japan
    • South Korea
    • India
    • Australia
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Egypt
    • UAE
    • Turkey

Frequently Asked Questions

Johnson and Johnson, GSK, and Serum Institute of India are the major manufacturing coming out with COVID-19 vaccines by the end of 2021.
The global COVID-19 vaccine market is likely to cross over $36 billion by the end of 2021.
AstraZeneca, GlaxoSmithKline, Moderna, Gamaleya, Bharat Biotech, and Pfizer are the major manufacturers of the COVID-19 vaccine.
APAC, Europe, and North America are expected to the largest revenue by the end of 2021.
Shortage of raw materials for vaccine manufacturing, lack of cold storage facilities, absence of skilled manpower, and the dearth of high-capacity production units are the major challenges faced by vendors.
Download Free Sample

The global COVID-19 vaccine market by revenue is expected to reach USD 42 billion in 2022

The following factors are likely to contribute to the growth of the COVID-19 market during the forecast period:

  • Increased Initiatives for COVID-19 Vaccination
  • The emergence of Next Generation Vaccine Platforms for COVID-19 Vaccine
  • Fast Regulatory Approvals for COVID-19 Vaccines

Base Year:                  2021

Forecast Year:           2022–2024

The study considers the COVID-19 vaccine market's present scenario and its market dynamics for the forecast period 2022−2024. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

Prominent Vendors  

  • AstraZeneca
    • Business Overview
    • Business Segment
    • Product Offerings
    • Key Strengths
    • Key Strategies
    • Key Opportunities
  • GlaxoSmithKline
  • Moderna
  • Gamaleya
  • Bharat Biotech
  • Pfizer
  • Johnson & Johnson
  • BioNTech
  • CureVac
  • Serum Institute of India
  • Novavax
  • Sinovac
  • Sinopharm

Upcoming Vendors

  • AnGes
    • Business Overview
  • AIVITA Biomedical
  • CanSinoBio
  • EuBiologics
  • Genexine
  • GreenLight Biosciences
  • Gennova
  • Heat Biologics
  • INOVIO
  • IIBR
  • Medicago
  • Symvivo
  • Valneva
  • Zydus Cadila

By Technology

  • Vector-based
  • Nucleic acid-based
  • Protein-based
  • Whole Virus

By Geography

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • Russia
  • APAC
    • China
    • Japan
    • South Korea
    • India
    • Australia
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Egypt
    • UAE
    • Turkey

1            Research Methodology

2            Research Objectives

3            Research Process

 

4            Scope & Coverage

4.1        Market Definition

4.1.1     Inclusions

4.1.2     Exclusions

4.2        Base Year

4.3        Scope Of The Study

4.3.1     Market Segmentation by Geography

 

5            Report Assumptions & Caveats

5.1        Key Caveats

5.2        Currency Conversion

5.3        Market Derivation

 

6            Market at a Glance

7            Introduction

7.1        Overview

 

8            Market Opportunities & Trends

8.1        Upcoming COVID-19 Vaccines

8.2        COVID-19 Vaccine Initiatives

8.3        Emergence of Next-Generation Vaccine Platforms

 

9            Market Growth Enablers

9.1        Faster Regulatory Approvals Of COVID-19 Vaccine

9.2        Rise In Number Of COVID-19 Patients

9.3        Contract Manufacturers Accelerating COVID-19 Vaccine Production

 

10         Market Restraints

10.1      COVID-19 Vaccine Distribution Among LMICs

10.2      Adverse Events & Negative Impact Of Approved Vaccines

10.3      Low Acceptance Of COVID-19 Vaccine

 

11         Market Landscape

11.1      Market Overview

11.2      COVID-19 Vaccine Pipeline

11.3      Market Size & Forecast

11.4      COVID-19 Supply Chain

11.5      Role of Contract Manufacturers in Manufacturing COVID-19 Vaccines

11.6      Five Forces Analysis

11.6.1   Threat of New Entrants

11.6.2   Bargaining Power of Suppliers

11.6.3   Bargaining Power of Buyers

11.6.4   Threat of Substitutes

11.6.5   Competitive Rivalry

 

12         Technology

12.1      Overview

12.2      Vector-Based COVID-19 Vaccine

12.2.1   Overview

12.3      Nucleic Acid-Based COVID-19 Vaccine

12.3.1   Overview

12.4      Protein-Based COVID-19 Vaccine

12.4.1   Overview

12.5      Whole Virus COVID-19 Vaccine

12.5.1   Overview

 

13         Geography

13.1      Market Snapshot & Growth Engine

13.2      Geographic Overview

 

14         APAC

14.1      Market Overview

14.2      Market Size & Forecast

14.3      Key Countries

14.3.1   China: Market Size & Forecast

14.3.2   India: Market Size & Forecast

14.3.3   Japan: Market Size & Forecast

14.3.4   South Korea: Market Size & Forecast

14.3.5   Australia: Market Size & Forecast

 

15         Europe

15.1      Market Overview

15.2      Market Size & Forecast

15.3      Key Countries

15.3.1   UK: Market Size & Forecast

15.3.2   Germany: Market Size & Forecast

15.3.3   Italy: Market Size & Forecast

15.3.4   France: Market Size & Forecast

15.3.5   Russia: Market Size & Forecast

15.3.6   Spain: Market Size & Forecast

 

16         North America

16.1      Market Overview

16.2      Market Size & Forecast

16.3      Key Countries

16.3.1   US: Market Size & Forecast

16.3.2   Canada: Market Size & Forecast

 

17         Middle East & Africa

17.1      Market Overview

17.2      Market Size & Forecast

17.3      Key Countries

17.3.1   Turkey: Market Size & Forecast

17.3.2   Saudi Arabia: Market Size & Forecast

17.3.3   Egypt: Market Size & Forecast

17.3.4   South Africa: Market Size & Forecast

17.3.5   UAE: Market Size & Forecast

 

18         Latin America

18.1      Market Overview

18.2      Market Size & Forecast

18.3      Key Countries

18.3.1   Brazil: Market Size & Forecast

18.3.2   Mexico: Market Size & Forecast

 

19         Competitive Landscape

19.1      Competition Overview

19.1.1   AstraZeneca

19.1.2   Moderna

19.1.3   Gamaleya

19.1.4   Pfizer

19.1.5   Johnson &Johnson

19.1.6   GlaxoSmithKline

19.1.7   Novavax

19.1.8   Bharath Biotech

19.1.9   CureVac

19.1.10 Serum Institute of India

19.1.11 Sinovac

19.1.12 Sinopharm

 

20         Key Company Profiles

20.1      AstraZeneca

20.1.1   Business Overview

20.1.2   Product Offerings

20.1.3   Key Strategies

20.1.4   Key Strengths

20.1.5   Key Opportunities

20.2      GlaxoSmithKline

20.2.1   Business Overview

20.2.2   Product Offerings

20.2.3   Key Strategies

20.2.4   Key Strengths

20.2.5   Key Opportunities

20.3      Moderna

20.3.1   Business Overview

20.3.2   Product Offerings

20.3.3   Key Strategies

20.3.4   Key Strengths

20.3.5   Key Opportunities

20.4      Gamaleya

20.4.1   Business Overview

20.4.2   Product Offerings

20.4.3   Key Strategies

20.4.4   Key Strengths

20.4.5   Key Opportunities

20.5      Bharat Biotech

20.5.1   Business Overview

20.5.2   Product Offerings

20.5.3   Key Strategies

20.5.4   Key Strengths

20.5.5   Key Opportunities

20.6      Pfizer

20.6.1   Business Overview

20.6.2   Product Offerings

20.6.3   Key Strategies

20.6.4   Key Strengths

20.6.5   Key Opportunities

20.7      Johnson & johnson

20.7.1   Business Overview

20.7.2   Product Offerings

20.7.3   Key Strategies

20.7.4   Key Strengths

20.7.5   Key Opportunities

20.8      BioNTech

20.8.1   Business Overview

20.8.2   Product Offerings

20.8.3   Key Strategies

20.8.4   Key Strengths

20.8.5   Key Opportunities

20.9      CureVac

20.9.1   Business Overview

20.9.2   Product Offerings

20.9.3   Key Strategies

20.9.4   Key Strengths

20.9.5   Key Opportunities

20.10    Serum Institute of India

20.10.1 Business Overview

20.10.2 Product Offerings

20.10.3 Key Strategies

20.10.4 Key Strengths

20.10.5 Key Opportunities

20.11    Novavax

20.11.1 Business Overview

20.11.2 Product Offerings

20.11.3 Key Strategies

20.11.4 Key Strengths

20.11.5 Key Opportunities

20.12    Sinovac

20.12.1 Business Overview

20.12.2 Product Offerings

20.12.3 Key Strategies

20.12.4 Key Strengths

20.12.5 Key Opportunities

20.13    Sinopharm

20.13.1 Business Overview

20.13.2 Product Offerings

20.13.3 Key Strategies

20.13.4 Key Strengths

20.13.5 Key Opportunities

 

21         Upcoming Vendors

21.1      AnGes

21.1.1   Business Overview

21.2      AIVITABiomedical

21.2.1   Business Overview

21.3      CanSinoBio

21.3.1   Business Overview

21.3.2   Product Offerings

21.4      eubiologics

21.4.1   Business Overview

21.5      Genexine

21.5.1   Business Overview

21.6      GreenLight Bioscience

21.6.1   Business Overview

21.7      Gennova

21.7.1   Business Overview

21.8      Heat Biologics

21.8.1   Business Overview

21.9      INOVIO

21.9.1   Business Overview

21.10    IIBR

21.10.1 Business Overview

21.11    medicago

21.11.1 Business Overview

21.12    Symvivo

21.12.1 Business Overview

21.13    Valneva

21.13.1 Business Overview

21.14    Zydus Cadila

21.14.1 Business Overview

 

22         Report Summary

22.1      Key Takeaways

22.2      Strategic Recommendations

 

23         Quantitative Summary

23.1      Market By Geography

23.2      North America

23.3      Europe

23.4      APAC

23.5      Latin America

23.6      Middle East & Africa

 

24         Appendix

24.1      Abbreviations

             

 

List Of Exhibits 

Exhibit 1             Global COVID-19 Vaccines Market

Exhibit 2             Market Size Calculation Approach 2021

Exhibit 3             Projected Manufacturing Capacity of Lead Companies Producing COVID-19 Vaccines by End of 2021 (in billions)

Exhibit 4             Impact of Upcoming COVID-19 Vaccine

Exhibit 5             Impact of COVID-19 Vaccine Initiatives

Exhibit 6             Impact of Emergence of Next-Generation Vaccine Platforms

Exhibit 7             Impact of Faster Regulatory Approvals of COVID-19 Vaccine

Exhibit 8             Impact of Rise in Number of COVID-19 Patients

Exhibit 9             COVID-19 Cases in Major Regions

Exhibit 10           Impact of Contract Manufacturers Accelerating COVID-19 Vaccine Production

Exhibit 11           Impact of COVID-19 Vaccine Distribution Among LMICs

Exhibit 12           Income Classification by Confirmed Doses Purchased ($ billions)

Exhibit 13           Impact of Adverse Events & Negative Impact of Approved Vaccines

Exhibit 14           Impact of Low Acceptance of COVID-19 Vaccine

Exhibit 15           People Not Willing to Take COVID-19 Vaccine (% share)

Exhibit 16           COVID-19 Vaccines Under Development by Dosage

Exhibit 17           COVID-19 Vaccines Under Development by Route of Administration

Exhibit 18           Global COVID-19 Vaccines Market 2021–2024 ($ billion)

Exhibit 19           COVID-19 Vaccine Logistics & Distribution

Exhibit 20           COVID-19 Vaccine Development 2021 (% share)

Exhibit 21           Five Forces Analysis 2021

Exhibit 22           Incremental Growth by Geography 2021 & 2024

Exhibit 23           Global COVID-19 Vaccines Market by Geography

Exhibit 24           Global COVID-19 Vaccines Market 2021- 2024 ($ million)

Exhibit 25           Global COVID-19 Vaccines Market 2021- 2024 (% share)

Exhibit 26           Production Capabilities of COVID-19 Vaccine Candidates Per Country (millions)

Exhibit 27           Income Classification by Confirmed Number of Doses Purchased by Country (Doses in billions)

Exhibit 28           APAC COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth

Exhibit 29           COVID-19 Vaccines Market in APAC  2021–2024 ($ billion)

Exhibit 30           Incremental Growth in APAC 2021 & 2024

Exhibit 31           COVID-19 Vaccines Market in China 2021–2024 ($ million)

Exhibit 32           COVID-19 Vaccines Market in India 2021–2024 ($ million)

Exhibit 33           COVID-19 Vaccines Market in Japan 2021–2024 ($ million)

Exhibit 34           COVID-19 Vaccines Market in South Korea 2021–2024 ($ million)

Exhibit 35           COVID-19 Vaccines Market in Australia 2021–2024 ($ million)

Exhibit 36           Europe COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth

Exhibit 37           COVID-19 Vaccines Market in Europe 2021–2024 ($ billion)

Exhibit 38           Incremental Growth in Europe 2021 & 2024

Exhibit 39           COVID-19 Vaccines Market in UK 2021–2024 ($ million)

Exhibit 40           COVID-19 Vaccines Market in Germany 2021–2024 ($ million)

Exhibit 41           COVID-19 Vaccines Market in Italy 2021–2024 ($ million)

Exhibit 42           COVID-19 Vaccines Market in France 2021–2024 ($ million)

Exhibit 43           COVID-19 Vaccines Market in Russia 2021–2024 ($ million)

Exhibit 44           COVID-19 Vaccines Market in Spain 2021–2024 ($ million)

Exhibit 45           North America COVID-19 Vaccine Market: Incremental Growth vs. Absolute Growth

Exhibit 46           COVID-19 Vaccine Developers in North America

Exhibit 47           COVID-19 Vaccines Market in North America 2021–2024 ($ billion)

Exhibit 48           Incremental Growth in North America 2021 & 2024

Exhibit 49           COVID-19 Vaccines Market in US 2021–2024 ($ million)

Exhibit 50           COVID-19 Vaccines Market in Canada 2021–2024 ($ million)

Exhibit 51           Middle East & Africa COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth

Exhibit 52           COVID-19 Vaccines Market in Middle East & Africa 2021–2024 ($ billion)

Exhibit 53           Incremental Growth in Middle East & Africa 2021 & 2024

Exhibit 54           COVID-19 Vaccines Market in Turkey 2021–2024 ($ million)

Exhibit 55           COVID-19 Vaccines Market in Saudi Arabia 2021–2024 ($ million)

Exhibit 56           COVID-19 Vaccines Market in Egypt 2021–2024 ($ million)

Exhibit 57           COVID-19 Vaccines Market in South Africa 2021–2024 ($ million)

Exhibit 58           COVID-19 Vaccines Market in UAE 2021–2024 ($ million)

Exhibit 59           Latin America COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth

Exhibit 60           COVID-19 Vaccine Market in Latin America 2021–2024 ($ billion)

Exhibit 61           Incremental Growth in Latin America 2021 & 2024

Exhibit 62           COVID-19 Vaccines Market in Brazil 2021–2024 ($ million)

Exhibit 63           COVID-19 Vaccines Market in Mexico 2021–2024 ($ million)

Exhibit 64           AstraZeneca Revenue 2017-2019 ($million)

Exhibit 65           AstraZeneca Research & Development Expenditure ($ million)

Exhibit 66           GlaxoSmithKline Revenue 2017-19 (billions)

Exhibit 67           Moderna Revenue 2017-2019 ($ million)

Exhibit 68           Moderna Research & Development Expenditure ($ million)

Exhibit 69           Pfizer Revenue 2017- 2019 ($ billion)

Exhibit 70           Pfizer Research & Development 2017- 2019 ($ billion)

Exhibit 71           Johnson & Johnson Revenue 2017- 2019 ($ million)

Exhibit 72           Johnson & Johnson Research & Development 2017- 2019 ($ million)

Exhibit 73           BioNTech Revenue 2017- 2019 (million)

Exhibit 74           BioNTech Research & Development 2017- 2019 ($ million)

Exhibit 75           Novavax Revenue 2017-2019 (million)

Exhibit 76           Novavax Research &Development Expenditure 2017-2019 (million)

             

List Of Tables   

Table 1               Key Caveats

Table 2               Currency Conversion 2013−2020

Table 3               Up-Coming COVID-19 Vaccines

Table 4               Comparison of Up-Coming COVID-19 Vaccine Platforms

Table 5               COVID-19 Cases in Top Ten Countries

Table 6               COVID-19 Vaccines EUA Approved as of Mid of 2021 January

Table 7               COVID-19 Vaccines Approved for Use in Various Countries

Table 8               COVID-19 Candidates in Clinical Phase Based on Vaccines Types

Table 9               List of COVID-19 Vaccines Under Phase II & III Clinical Trial

Table 10             List of COVID-19 Vaccines Under Phase I & II Clinical Trial

Table 11             List of COVID-19 Vaccines Under Phase I & Pre-Clinical Trial

Table 12             Key companies & CMOs Agreements for COVID-19 Vaccine (millions)

Table 13             EUA-Approved COVID-19 Vaccines

Table 14             COVID-19 Vaccines Based on Vector Platform Under Development

Table 15             COVID-19 Vaccines Based on Nucleic Acid Platform Under Development

Table 16             COVID-19 Vaccines Based on Protein Platform Under Development

Table 17             COVID-19 Vaccines Based on Whole Virus Platform Under Development

Table 18             Regional Confirmed COVID-19 Cases WHO (as of 2021 February)

Table 19             Countries with Highest COVID-19 Cases & Deaths

Table 20             List of Agreements Signed for COVID-19 Vaccines

Table 21             Approved Vaccines for COVID-19 in UK

Table 22             UK Agreement with Companies for COVID-19 Vaccine (million)

Table 23             List of Agreements Signed for COVID-19 Vaccines

Table 24             Approved Vaccines for COVID-19 in US

Table 25             US Agreement with Companies for COVID-19 Vaccine (million)

Table 26             List of Agreements Signed for COVID-19 Vaccines

Table 27             List of Agreements Signed for COVID-19 Vaccines.

Table 28             List of Agreements Signed for COVID-19 Vaccines with AstraZeneca

Table 29             List of Agreements Signed for COVID-19 Vaccines with Moderna

Table 30             List of Agreements Signed for COVID-19 Vaccines with Pfizer

Table 31             List of Agreements Signed for COVID-19 Vaccines with Johnson & Johnson

Table 32             List of Agreements Signed for COVID-19 Vaccines with GSK

Table 33             List of Agreements Signed for COVID-19 Vaccines with Novavax

Table 34             List of Agreements Signed for COVID-19 Vaccines with CureVac

Table 35             List of Agreements Signed for COVID-19 Vaccines with SinoVac

Table 36             AstraZeneca: Major Product Offerings

Table 37             GlaxoSmithKline: Major Product Offerings

Table 38             Moderna: Major Product Offerings

Table 39             Gamaleya: Major Product Offerings

Table 40             Bharat Biotech: Major Product Offerings

Table 41             Pfizer: Major Product Offerings

Table 42             Johnson & Johnson: Major Product Offerings

Table 43             BioNTech: Major Product Offerings

Table 44             CureVac: Major Product Offerings

Table 45             Serum Institute of India: Major Product Offerings

Table 46             Novavax: Major Product Offerings

Table 47             Sinovac: Major Product Offerings

Table 48             Sinopharm: Major Product Offerings

Table 49             CanSinoBio: Major Product Offerings

Table 50             Global COVID-19 Vaccines Market by Geography 2021−2024 ($ million)

Table 51             Global COVID-19 Vaccines Market by Geography 2021−2024 (%)

Table 52             North America COVID-19 Vaccines Market 2021−2024 ($ million)

Table 53             North America COVID-19 Vaccines Market 2021−2024 (%)

Table 54             Europe COVID-19 Vaccines Market 2021−2024 ($ million)

Table 55             Europe COVID-19 Vaccines Market 2021−2024 (%)

Table 56             APAC COVID-19 Vaccines Market 2021−2024 ($ million)

Table 57             APAC COVID-19 Vaccines Market 2021−2024 (%)

Table 58             Latin America COVID-19 Vaccines Market 2021−2024 ($ million)

Table 59             Latin America COVID-19 Vaccines Market 2021−2024 (%)

Table 60             Middle East & Africa COVID-19 Vaccines Market 2021−2024 ($ million)

Table 61             Middle East & Africa COVID-19 Vaccines Market 2021−2024 (%)

Select a license type that suits your business needs

Single User Licence
$3750.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5 User Licence
$4250.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
$5250.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

YOU CAN GET A FREE SAMPLE OF THIS REPORT!

Fill out your details & get your free sample

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Our Clients

Licence Types What are these?

Our Clients Speak

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date